Alphamab Oncology Announces Interim Phase III Results for Anbenitamab in HER2‑Positive Gastric Cancer
Alphamab Oncology (HKG: 9966) today disclosed the first interim data from its Phase III study evaluating...
Drug
Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC
Multitude Therapeutics, Inc. today released preliminary data from its ongoing Phase I/II, open‑label, multicenter, dose‑escalation and...
Eli Lilly Announces Long‑Term Survival Benefit of Abemaciclib in Early Breast Cancer
Eli Lilly & Company (NYSE: LLY) today disclosed the long‑term benefits of abemaciclib in hormone‑receptor‑positive...
Kelun-Biotech’s Trastuzumab Botidotin Approved by NMPA for HER2-Positive Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on October 17, 2025, that its Human...
Huadong Medicine Secures NMPA Approval for Relmapirazin Injection, Complementing MediBeacon TGFR Device
Huadong Medicine (SHE: 000963) announced that China’s National Medical Products Administration (NMPA) has granted marketing...
CStone’s Sugemalimab Receives Positive EMA Opinion for Stage III NSCLC
CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal...
Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase II/III Trial
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food...
Chia Tai Tianqing Secures NMPA Approval for Phase III Trial of TQB2868 + Anlotinib in First‑Line mPDAC Therapy
Chia Tai Tianqing, a wholly‑owned subsidiary of Sino Biopharmaceutical (HKG: 1177), announced today that the...
Lepu Biopharma Enrolls First Patient in Phase II Trial of MRG006A, the World’s First GPC3‑Targeting ADC
Lepu Biopharma Co., Ltd. (HKG: 2157) announced today that it has successfully enrolled the first...
HELP Therapeutics Secures NMPA Approval for HiCM388, China’s First Cell‑Based Therapy for STEMI
HELP Therapeutics Corp., a pioneer in cell‑based therapeutics, announced that the National Medical Products Administration...
Sino Biopharmaceutical’s Partner CTTQ Secures Breakthrough Therapy Designation for TQ‑B3234 Capsule in China
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of China‑based Sino Biopharmaceutical Ltd. (HKG: 1177), today...
Pfizer Reports Positive Phase 3 HER2CLIMB‑05 Results for TUKYSA (Tucatinib) in First‑Line HER2+ MBC
Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase 3 HER2CLIMB‑05 trial, evaluating...
Shenzhen Kangtai Secures 530 Million Yuan Technology Transfer for Klebsiella Pneumoniae Vaccine
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) today announced the signing of a technology‑transfer...
Eisai & Biogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer’s Disease
Japanese pharmaceutical giant Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB)...
Chengdu Olymvax Biopharmaceuticals & Delonix Bioworks Announce Joint Development of Gene‑Engineered Pertussis Vaccine
Chengdu Olymvax Biopharmaceuticals Inc. and Delonix Bioworks Co., Ltd. today announced a strategic collaboration and...
Jiudian Pharma Acquires Chengdu Peide’s JIJ02 Gel, Advancing a Novel Acne Treatment into Phase 1
Hunan Jiudian Pharmaceutical Co., Ltd. (SHE: 300705) today announced the acquisition of all developed results...
Bio‑Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506
Bio‑Thera Solutions (SHA: 688177) today announced the expansion of its collaboration with Intas Pharmaceuticals for...
Maxvax Biotech Secures NMPA Acceptance for Its Recombinant Herpes Zoster Vaccine
Maxvax Biotech announced today that the China National Medical Products Administration (NMPA) has accepted the...
CSPC Pharmaceutical Group Announces NMPA Acceptance of Efmedaglutide Alfa Injection for Long‑Term Weight Management
CSPC Pharmaceutical Group Limited (HKG: 1093) today announced that the National Medical Products Administration (NMPA)...
UCB Biosciences Receives NMPA Marketing Authorization for Zilucoplan (Zilbrysq) in Adult Generalized Myasthenia Gravis
UCB S.A. (EBR: UCB), a global biopharmaceutical company, announced today that the National Medical Products...